Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir + elbasvir for chronic hepatitis C genotype 1b with compensated cirrhosis after prior treatment failure
2015-004713-24Phase 3Terminated
- Sponsor
- Humanitas Research Hospital
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of grazoprevir and elbasvir in chronic hepatitis C (CHC) and Cirrhosis, sponsored by Humanitas Research Hospital. Primary endpoint: Sustained virologic response at 12 weeks after treatment. Started Nov 2018; status: terminated.
02
Drugs
grazoprevirelbasvir
03
Conditions
chronic hepatitis C (CHC)Cirrhosis
Beyond the preview
Go deeper on 2015-004713-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004713-24.